# Binding affinity, occupancy and enzyme kinetics

Source: https://onco.cc/terms/binding-affinity-and-kinetics/  
OnCo record `binding-affinity-and-kinetics` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Binding strength, the fraction of sites occupied and the speed of a reaction describe different things. Each measurement needs its experimental conditions.

## Summary

For a simple reversible binding equilibrium, Kd is the product of free partner concentrations divided by complex concentration; lower Kd means tighter binding under those conditions. For identical independent sites with one ligand and no competition, fractional occupancy is L / (Kd + L), where L is free ligand concentration. Half occupancy occurs at L = Kd in that model. Total added ligand need not equal free ligand. Affinity for one partner does not establish specificity against other partners.

## Fields

- Kind: Term
- Last checked: 2026-11-13
- Also known as: binding affinity; dissociation constant; Kd; receptor occupancy; Michaelis constant; Km; enzyme turnover

## Notes

- For a suitable Michaelis-Menten enzyme model, Km is the substrate concentration at half the maximum initial reaction rate. It depends on the catalytic mechanism and conditions and is not generally Kd. Turnover concerns reaction cycling, not binding strength.
- IC50 is half inhibition of a specified assay response; EC50 describes half of a defined functional response change. Substrate/ATP concentrations, enzyme or receptor amount, timing and assay design affect these measures. A biochemical inhibition value, a cell-growth value and a clinical outcome are separate evidence.
- In a fictional one-site equilibrium example, free ligand and Kd are both 10 nM. With identical independent sites and no competing ligand, occupancy is 10 divided by (10 plus 10), or one half. Five occupied symbols among ten illustrate that model fraction; they are not a guaranteed realised count, a dose recommendation or five dead cells. Binding and release can leave a ligand unchanged. A separate catalytic example changes a substrate bond, retains its atoms in the products and reuses the enzyme. Binding, chemical transformation and a later cellular response therefore need separate measurements.

## Sources

- A guide to simple, direct, and quantitative in vitro binding assays.: https://pubmed.ncbi.nlm.nih.gov/31453222/
- Operational models of pharmacological agonism.: https://pubmed.ncbi.nlm.nih.gov/6141562/
- IUPAC: affinity and pharmacological efficacy: https://iupac.qmul.ac.uk/medchem/ah.html
- OpenStax Biology 2e: 6-5-enzymes: https://openstax.org/books/biology-2e/pages/6-5-enzymes
- Classroom model and derivation of Michaelis-Menten parameters; not an enzyme experiment: https://pubmed.ncbi.nlm.nih.gov/17146042/
- GraphPad Prism: one-site specific-binding model and equilibrium half-maximum: https://www.graphpad.com/guides/prism/latest/curve-fitting/reg_one_site_specific.htm

## Connected records

- terms: [Agonist and antagonist](https://onco.cc/terms/agonist-antagonist/), [Biased agonism and pathway-dependent receptor response](https://onco.cc/terms/biased-agonism/), [Drug response and drug sensitivity (IC50, AUC)](https://onco.cc/terms/drug-response-sensitivity/), [Enzyme](https://onco.cc/terms/enzyme/), [Kinase](https://onco.cc/terms/kinase/), [Ligand](https://onco.cc/terms/ligand/), [Protein structure, domains and model confidence](https://onco.cc/terms/protein-structure-and-domains/), [Receptor](https://onco.cc/terms/receptor/), [Receptor reserve and system-dependent response](https://onco.cc/terms/receptor-reserve/)

---
JSON: https://onco.cc/api/v1/entities/binding-affinity-and-kinetics.json